about
Recent Progress in Therapeutic Treatments and Screening Strategies for the Prevention and Treatment of HPV-Associated Head and Neck CancerTargeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience.A pilot study of nimotuzumab plus single agent chemotherapy as second- or third-line treatment or more in patients with recurrent, persistent or metastatic cervical cancer.Depletion of the cisplatin targeted HMGB-box factor UBF selectively induces p53-independent apoptotic death in transformed cells.New pharmacotherapy options for cervical cancer.Liberation of functional p53 by proteasome inhibition in human papilloma virus-positive head and neck squamous cell carcinoma cells promotes apoptosis and cell cycle arrest.The effects of narrow-band middle infrared radiation in enhancing the antitumor activity of paclitaxel.
P2860
Q26782255-8450C977-C107-40C1-A0DB-619249A38232Q34957243-16477F70-9443-4499-A2F5-B24096E13152Q36214463-7599ACE3-8BA0-4BB2-BD15-78B6509B7C40Q36413821-E9BFD679-F9A9-4E08-A06D-C3904F7F1DD7Q38160897-56334579-DC06-4E3F-AD17-BFE0CED2330BQ39191981-58E09609-93DF-41E5-A35F-4098B3E27C7AQ46709199-38E91FCE-2983-4787-B587-E8A43A963397
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Emerging drugs for cervical cancer.
@en
type
label
Emerging drugs for cervical cancer.
@en
prefLabel
Emerging drugs for cervical cancer.
@en
P2093
P2860
P1476
Emerging drugs for cervical cancer
@en
P2093
Alfonso Dueñas-Gonzalez
Jaime Coronel
Lucely Cetina
P2860
P304
P356
10.1517/14728214.2012.683409
P407
P577
2012-04-25T00:00:00Z